Gold Nanoparticles for Brain Tumor Imaging: A Systematic Review

Antonio Meola1*, Jianghong Rao2, Navjot Chaudhary1, Mayur Sharma3 and Steven D. Chang1

1Department of Neurosurgery, Stanford University, Stanford, CA, United States, 2Department of Radiology, Stanford University, Stanford, CA, United States, 3Department of Neurosurgery, University of Louisville, Louisville, KY, United States

Background: Demarcation of malignant brain tumor boundaries is critical to achieve complete resection and to improve patient survival. Contrast-enhanced brain magnetic resonance imaging (MRI) is the gold standard for diagnosis and pre-surgical planning, despite limitations of gadolinium (Gd)-based contrast agents to depict tumor margins. Recently, solid metal-based nanoparticles (NPs) have shown potential as diagnostic probes for brain tumors. Gold nanoparticles (GNPs) emerged among those, because of their unique physical and chemical properties and biocompatibility. The aim of the present study is to review the application of GNPs for in vitro and in vivo brain tumor diagnosis.

Methods: We performed a PubMed search of reports exploring the application of GNPs in the diagnosis of brain tumors in biological models including cells, animals, primates, and humans. The search words were “gold” AND “NP” AND “brain tumor.” Two reviewers performed eligibility assessment independently in an unblinded standardized manner. The following data were extracted from each paper: first author, year of publication, animal/cellular model, GNP geometry, GNP size, GNP coating [i.e., polyethylene glycol (PEG) and Gd], blood-brain barrier (BBB) crossing aids, imaging modalities, and therapeutic agents conjugated to the GNPs.

Results: The PubMed search provided 100 items. A total of 16 studies, published between the 2011 and 2017, were included in our review. No studies on humans were found. Thirteen studies were conducted in vivo on rodent models. The most common shape was a nanosphere (12 studies). The size of GNPs ranged between 20 and 120 nm. In eight studies, the GNPs were covered in PEG. The BBB penetration was increased by surface molecules (nine studies) or by means of external energy sources (in two studies). The most commonly used imaging modalities were MRI (four studies), surface-enhanced Raman scattering (three studies), and fluorescent microscopy (three studies). In two studies, the GNPs were conjugated with therapeutic agents.

Conclusion: Experimental studies demonstrated that GNPs might be versatile, persistent, and safe contrast agents for multimodality imaging, thus enhancing the tumor edges pre-, intra-, and post-operatively improving microscopic precision. The diagnostic GNPs might also be used for multiple therapeutic approaches, namely as “theranostic” NPs.

Keywords: gold, nanoparticle, brain tumor, Raman scattering, magnetic resonance imaging, photoacoustic imaging, glioma, blood-brain barrier
INTRODUCTION

Surgery is the mainstay of primary brain tumor management (1). The goal of image-guided neurosurgery for primary brain tumors is to achieve maximal tumor resection, while minimizing neurological morbidity and mortality related to brain manipulation of cortical and subcortical structures (2, 3). Post-surgical residual enhancing tumor volume is a strong significant negative predictor of patient survival, especially in high-grade gliomas (4). Thus, the delineation of tumor boundaries is crucial for optimizing surgical resection and improving overall survival.

Although brain magnetic resonance imaging (MRI) is still the gold standard for brain tumor diagnosis (5, 6), it is accuracy in delineating brain tumor boundaries is limited by the pharmacological properties of the commonly used gadolinium (Gd)-based contrast agents. Indeed, these agents enhance brain tumor regions where there are major defects and abnormal permeability of the blood–brain barrier (BBB) (7). However, BBB permeability is almost normal at in the most peripheral, yet most actively replicating and invasive portions of high-grade tumors (4). Thus, visualization of tumor edges can be sub-optimal as peripheral tumor debulking may be limited, while a more extensive resection could positively impact patient survival (8). In a similar fashion, low-grade primary brain tumors induce a limited increase in BBB permeability, preventing a clear delineation of tumor edges (9). Thus, there is a need for new imaging techniques, enabling the neurosurgeon to better visualize tumor edges, regardless of BBB permeability and tumor histology and grade.

Recently, solid metal-based nanoparticles (NPs) have shown potential as diagnostic probes for brain tumors (10, 11). Nanotechnology has emerged with the goal of better understanding and manipulating materials in order to create NPs ranging from 1 to 100 nm in diameter (11). The potential of the NPs as diagnostic (and therapeutic) agents in neuro-oncology can be attributed to their chemical and physical properties, including their small size, physiological stability, and biocompatibility (11). Several NPs were tested for brain tumor imaging, including quantum dots, iron oxide NPs, superparamagnetic iron oxide NPs, carbon nanotubes, dendrimers, polyelectrolyte complex NPs, calcium phosphate NPs, perfluorocarbon NPs, and lipid-based NPs (11). Nonetheless, the main limitation for the application of metallic NPs in vitro and in vivo is cyto-toxicity due to degradation and release of toxic metal ions (12).

Gold nanoparticles (GNPs) were discovered more than one century ago. Given their remarkable biocompatibility, negligible toxicity, high-atomic number, and high-X-ray absorption coefficient, they have received significant interest recently for use in multiple imaging technologies (13). Additionally, GNP’s synthesis is technically easy and cost effective (14).

To the best our knowledge, this is the first literature review to explore the application of GNPs in brain tumor diagnosis. We aim to: (1) define the main structural features of GNPs that are critical for their biological, toxic, and physical (radiological) properties; (2) review the radiological techniques that can be used in conjunction with GNPs; and (3) review experimental models for testing GNPs and explore any potential studies in humans.

Future research could include creating new GNPs specifically optimized for particular radiological techniques, as well as for preparing experimental models to test GNPs.

MATERIALS AND METHODS

The present review was conducted according to the PRISMA statement criteria (15). The literature search was updated to April 30, 2017. No other temporal limits were applied. The search was open to both in vitro and in vivo studies. Inclusion criteria included GNPs to diagnose any kind of brain tumor in biological models including cells, animals, primates, and humans. The review included only original papers published in Pubmed-indexed peer-review journals, clearly stating the structural features of the GNPs (listed below), the experimental model/s, and the radiological technique/s applied in conjunction with the GNPs. Exclusion criteria included: papers not describing original research (i.e., reviews, perspectives, letters to the editor, commentaries, and abstracts), papers in languages other than English, description of new chemical or physical properties of GNPs without application of biological models, and papers focusing on nanotechnology but not primarily on brain tumor diagnosis or GNPs. The search was performed using the PubMed database and by scanning reference lists of the resulting articles. The search terms were “gold” AND “NP” AND “brain tumor.” Eligibility assessment was performed independently in an unblinded standardized manner by two reviewers (Antonio Meola and Navjot Chaudhary). Disagreements between reviewers were resolved by consensus. The following data were extracted from each paper: first author, year of publication, animal/cellular model, GNP route of administration, GNP geometry, GNP size, GNP coating and imaging tags, BBB-crossing enhancers, imaging modalities applied in conjunction with the GNPs, and main conclusions of the study. Unfortunately, a quantitative comparison between studies or groups was not possible because of heterogeneity of the biological models and technical discrepancies between different GNP formulations. Therefore, no statistical analysis was performed.

RESULTS

A total of 16 studies were included in our review. The PubMed search yielded 100 items. One duplicate was found. Among the collected studies, 85 were discarded because they met the exclusion criteria: reviews (16), commentaries (2), conference proceedings (1), topics different than brain tumor (17), topics different than GNPs (2), topics different than diagnosis (i.e., brain tumor therapy) (18), and applications on non-biological models (4). Two (2) citations (19, 20) were added after reviewing the bibliographies of the included papers (Figure 1). The studies...
Sixteen studies were published between 2011 and 2017. No studies on humans were found. Eight studies were conducted in vivo on rodent models, three studies were performed in vitro on brain tumor cells, and five studies were done in vitro and in vivo. In all the studies in vitro, the GNPs were loaded into the brain tumor cells; while in the studies in vivo, the GNPs were injected intravenously into the tail vein of the rodent models with two exceptions. In one study, the GNPs were inoculated into primary breast cancer in order to detect metastatic spread to the central nervous system (32); in another study, the GNP-loaded xenograft was heterotopically injected into the subcutaneous tissue (16).

The cellular models more commonly used in vitro were the U87 GBM cells (six studies), the U227 GBM cells (two studies), and the U251 GBM cells (two studies). Among all the other in vitro only models, one study was performed on a cellular model different than glioma, namely on melanoma.

FIGURE 1 | Flow-diagram of study selection, according to PRISMA criteria (15).
| Reference | Model | Route of adm. | Shape | Size (nm) | GNP coating and imaging tags | BBB-crossing enhancers | Imaging modality | Main conclusions |
|-----------|-------|---------------|-------|-----------|-----------------------------|------------------------|------------------|------------------|
| Gao et al. (21) | In vivo: U87 GBM orthotopic xenograft in nude mice | I.V. | GNS | 20 | PEG, Gd-DTPA, Raman tag (IR783B), Alkyne/azide group | LRp-1 | MRI, SERS microscopy | – The acidic brain tumor environment triggers nanoclustering of alkyne-GNS with azide-GNS, preventing them from returning in the blood stream. – Xenograft edges are persistently enhanced by Gd-DTPA. – Tumor resection is guided by SERS signal – RGdK-GNSSs penetrate the GBM significantly better than RADyK-GNSS (non-integrin targeted GNSS). – RGdK-GNSSs define the tumor edges, the local infiltration and satellite foci |
| Huang et al. (20) | In vivo: RCAS-PDGF/N-tva transgenic mouse model of GBM (overexpression of integrin αvβ3) | I.V. | GNS/ GNS | 60 | PEG, Raman tag (N,N-dimethylformamide) RGdK/RADyK | RGdK | SERS microscopy | – RGDyK-GNSSs penetrate the GBM significantly better than RADyK-GNSS (non-integrin targeted GNSS). |
| Pohlmann et al. (22) | In vitro: GS9-6/NOTCH1 + GBM cells | Culture | GNR | 50 | P/P | No | TEM | – TEM allows visualizing the interaction between cells and GNP's at different GNP concentrations, and between GNP's within the tumor cells |
| Lai et al. (23) | In vivo: U87 GBM and GBM8401 glioma orthotopic xenograft in mice | Culture | GNS | N/A | Fluorescent tag (MUA) | No | SEM, Optical microscopy | – By complementing the SEM imaging with optical imaging, the GNP's can be identified and localized within the tumor itself |
| Kempen et al. (24) | In vivo: U87 GBM xenograft in severe combined immunodeficiency mice | I.V. | GNS | 60 | Silica shell, Gd, Raman tag trans-1,2-bis(4-pyridyl)-ethylene PEG, Fluorescent tag (Po4) | No | SEM, Optical microscopy | – By complementing the SEM imaging with optical imaging, the GNP's can be identified and localized within the tumor itself |
| Dixit et al. (25) | In vitro: U87 GBM cells, U227 GBM cells, in vivo: U87 GBM orthotopic xenograft in mice | Culture/I.V. | GNS | 41 | PEG, Fluorescent tag (Po4) | Ti | Fluo | – Y conjugation significantly enhanced the GNP's uptake by GBM orthotopic xenograft with respect to the GNP's non-conjugated with Ti. – Regardless of the Ti conjugation, the GNP's were found to be highly specific for brain tumor tissue, with negligible accumulation in other organs – Double-targeted GNP's cross the BBB more efficiently than the single-targeted GNP-Po4, leading to higher accumulation levels and to a faster rate of accumulation. |
| Dixit et al. (26) | In vitro: U87 GBM cells U227 GBM cells. In vivo: U87 GBM orthotopic graft in mice | Culture/I.V. | GNS | 41 | PEG, Fluorescent tag (Po4) | Ti, FGF | Fluo | – Double-targeted GNP's accumulate in critical organs less than single-targeted GNP's |
| Cheng et al. (27) | In vitro: U87 GBM cells, U251 GBM cells, GBM43 cells, GL261 GBM cells | Culture/I.V. | GNS | 21 | PEG, Gd, Dox TAT | MRgFUS, MRI, TEM, Fluo, SERS microscopy | – When compared with Gd-chelates alone, the TAT-GNP-Gd conjugates cause more intense and more lasting enhancement of the brain tumor with signal still detectable after 24 h. – GNP's are washed out from the normal brain within 24 h. – TAT-GNP conjugated with GNP's that are selectively uptaken by tumor cells that are killed. |
| Diaz et al. (28) | In vitro: gliosarcoma 9L cells GBM cells, C6 glioma cells, U87 GBM cells, A172 GBM cells, U251 GBM cells, U373 GBM cells, BT2012036 oligodendroglioma, GLINS1 GBM stem cells | Culture (U87 model), I.V or intra-arterial (9L model) | GNS | 50/120 | PEG, Silica shell, Fluorescent tag (Cyto647) Raman tag (trans-1,2-Bis(4-pyridyl)-ethylene) | MRgFUS, anti-EGFR Ab | MRI, TEM, Fluo, SERS microscopy | – Fluo allows monitoring the growth of the GNP's-loaded xenograft. – GNP's cross the BBB in areas treated with MRgFUS. – Anti-EGFR functionalization promotes GNP's uptake by tumor cells. – SERS-active GNP's allow enhancement of the brain tumor edges after MRgFUS in vivo |

(Continued)
Yuan et al. (29)  
**In vivo:** D270 glioma xenograft in mice  
**I.V.** GNS 80 PEG  
**BBB-coding enhancers:** Ultra-short pulsed laser  
**Imaging modality:** MPM  
**Main conclusions:** - MPM allows micro-angiographic visualization of GNP’s in the tumor vasculature.
- Low-potency image-guided pulsed laser irradiation allows selective GNSs uptake by the tumor.

Schultke et al. (30)  
**In vivo:** GNP-loaded C6 glioma xenograft in Wistar rats  
**Culture** GNS 50 No  
**BBB-coding enhancers:** No  
**Imaging modality:** SynCT  
**Main conclusions:** - SynCT allows single-cell spatial resolution of GNP-loaded glioma xenograft **ex vivo**
- SynCT allows 3D reconstruction and volumetric analysis of GNP-loaded tumor xenograft **in vivo** and **ex vivo**.

Astolfi et al. (31)  
**In vivo:** GNP-loaded F98 glioma xenograft in mice  
**Culture** GNS 50 No  
**BBB-coding enhancers:** No  
**Imaging modality:** SynCT  
**Main conclusions:** - Tumor doubling time is assessed by SynCT.
- Photothermal imaging allows to identify GNRs labeled cancer cells and to detect the intracellular clustering of GNRs.

Nedosekin et al. (32)  
**In vivo:** B16F10 Melanoma cells, MDA-MB-231 Breast cancer cells  
**In vivo:** MDA-MB-231 Breast cancer xenograft implanted in mice breast  
**Culture** GNR <100 PEG  
**BBB-coding enhancers:** Folate, EpCam, CD 45  
**Imaging modality:** PACT, PTC  
**Main conclusions:** - By applying a laser over the cisterna magna of mice, the GNRs were used to label and detect breast cancer metastasis to the CNS before those became macroscopically evident.

Cho et al. (16)  
**In vitro:** GNP-loaded U87 glioma cells.  
**In vivo:** GNP-loaded U87 glioma suspension injected subcutaneously in mice  
**Culture** GNC 50 No  
**BBB-coding enhancers:** RGDyK (the experiment did not require BBB crossing)  
**Imaging modality:** MPM, PAM  
**Main conclusions:** - MPM estimates the intracellular uptake of GNCs by glioma cells in **vitro**.
- PAM allowed estimating the total number of RADyK-GNCs within the tumor at each time point and quantifying the growth of the tumor.

Kircher et al. (19)  
**In vitro:** eGFP+U87MG cells.  
**In vivo:** eGFP-U87MG xenograft in mice  
**Culture/I.V.** GNS 60 Silica shell, Gd, Raman tag (trans-1,2-bis(4-pyridyl)-ethylene) Aka MPR NP  
**BBB-coding enhancers:** No  
**Imaging modality:** MRI, PAM, SERS microscopy  
**Main conclusions:** - MPR NP allows MRI, photoacoustic and Raman imaging.
- MRI, photoacoustic, and Raman imaging co-localize in vivo between them and with histological analysis.

Noreen et al. (33)  
**In vivo:** U87 GBM cells xenograft in mice injected with GPNs  
**I.V.** GNS 20 No  
**BBB-coding enhancers:** No  
**Imaging modality:** FTIR  
**Main conclusions:** - FTIR in vivo reveals microvascular architecture of brain tumors (enhanced by BaSO4 nanoparticles) and their micro-fenestration (revealed by GNP leak into the extravascular space).
TABLE 2 | Experimental models used in the included studies.

| Experimental model | Examples (number of studies$^a$) |
|--------------------|----------------------------------|
| **In vitro**        |                                   |
|                     | U87 GBM cells (6)                 |
|                     | U227 GBM cells (2)                |
|                     | U251 GBM cells (2)                |
|                     | GS9-6/NOTCH1 + GBM cells          |
|                     | 9L gliosarcoma cells, C6 glioma cells, A172 |
|                     | GBM cells, U373 GBM cells, BT2012036 |
|                     | oligodendroglioma, GLINS1 GBM stem cells |
|                     | B16F10 Melanoma cells            |
|                     | MDA-MB-231 Breast cancer cells   |
| **In vivo**         |                                   |
|                     | U87 GBM orthotopic xenograft (8)  |
|                     | U87 GBM heterotopic xenograft     |
|                     | RCAS-PDGF/N-tva transgenic mouse model of GBM |
|                     | GBM8401 orthotopic xenograft      |
|                     | TS543 GBM orthotopic xenograft    |
|                     | 9L gliosarcoma orthotopic xenograft |
|                     | C6 glioma orthotopic xenograft    |
|                     | F98 glioma orthotopic xenograft   |
|                     | MDA-MB-231 breast cancer cells   |

$^a$Number is reported only if > 1.

GBM, glioblastoma.

TABLE 3 | Structural components of the GNPs for brain tumor diagnosis.

| Structural features of GNPs | Examples (number of studies$^a$) |
|----------------------------|----------------------------------|
| GNP shape                  | Gold nanosphere (GNS) (12)       |
|                            | Gold nanostar (GNSt) (2)         |
|                            | Gold nanorod (GNR) (2)          |
|                            | Gold nanocage (GNC)             |
| GNP size                   | 20–120 nm                       |
| GNP coating                | Polyethylene glycol (PEG) (8)   |
|                            | Silica shell (2)                |
|                            | PEG and silica shell            |
| GNP imaging tags           | Trans-1,2-bis(4-pyridyl)-ethylene (3) |
|                            | IR783B                           |
|                            | N,N-dimethylformamide           |
| Fluorescent tag            | Phthalocyanine 4 (Pc4) (2)      |
|                            | Mercapto-urodacetic acid (MUA)  |
|                            | Cytochrome 647 (Cyto 647)       |
| MRI tag                    | Gadolinium (4)                  |
| BBB-crossing enhancers     | RGDyK (2)                       |
| (on-surface)               | transferrin (TR) (2)            |
|                            | Fibroblast growth factor (FGF)  |
|                            | Low-density lipoprotein-receptor-related protein-1 (LRP-1) |
|                            | Transactivator of transcription (TAT) |
|                            | Anti-epidermal growth factor receptor antibody (anti-EGFR AB) |
|                            | Folate, EpCam, CD 45            |
|                            | MR-guided focussed ultrasound   |
|                            | ultra-short pulsed laser        |

$^a$Number is reported only if > 1.

GNP, gold nanoparticle.

TABLE 4 | Imaging techniques applied in conjunction with gold nanoparticles (GNPs) for brain tumor diagnosis.

| Imaging resolution | Examples (number of studies$^a$) |
|--------------------|----------------------------------|
| **Macroscopic level** | MRI (4)                        |
|                     | Synchrotron-based CT            |
| **Microscopic level** | Surface-enhanced Raman scattering microscopy (4) |
|                     | Photoacoustic imaging/photoacoustic microscopy (2) |
|                     | Photothermal cytometry          |
|                     | Tridimensional X-ray microscopy |
|                     | Optical microscopy              |
|                     | Fourier-transform infrared imaging |
| **Subcellular level** | Transmission electron microscopy (2) |
|                     | Multiphoton microscopy (2)      |
|                     | Scanning electron microscopy    |

$^a$Number is reported only if > 1.

and breast cancer cells (32). In vivo, the most commonly used model was the U87 orthotopic xenograft (eight studies). A single study was performed on a cellular model different than glioma, using a breast cancer orthotopic xenograft (32). Another group used an RCAS-PDGF/N-tva transgenic mouse model of GBM (20).

The shape of GNPs was nanosphere (GNS) in 12 studies, nanostar (GNSt) in 2 studies, nanorod (GNR) in 2 studies, and nanocage (GNC) in one study. The size of GNPs ranged between 20 and 120 nm. Twelve studies used GNPs with size equal or less than 60 nm. Noticeably, the GNPs with a diameter of 120 nm crossed the BBB, after permeabilization of the brain tumor region with MRI-guided focused ultrasound (MRgFUS) (28).

Among the 13 in vivo studies, the GNPs were covered of polyethylene glycol (PEG) in 8 studies (namely PEGylated), the GNPs were covered with a silica shell in 2 studies, and with both in one case. Several imaging modalities used GNPs to diagnose and follow tumor growth at a macroscopic and cellular level, and to define the biodistribution of GNPs at a subcellular level. The imaging techniques are summarized in Table 5. The most commonly used imaging modalities were MRI (four studies), surface-enhanced Raman scattering (SERS) (three studies), and fluorescent microscopy (three studies). All of these techniques required specific molecules attached to the GNP surface, in order to make them detectable within the tumor cells. All the MRI-enhancing GNPs carried Gd-chelates on their surface; for fluorescent microscopy purpose, the most commonly used fluorescent tag was the phthalocyanine 4 (Pc4) (two studies); and the most commonly used SERS-active tag was the trans-1,2-bis(4-pyridyl)-ethylene (three studies).

In order to increase the penetration of the GNPs through the BBB and their uptake by tumor cells, the GNPs were functionalized with different molecules on their surface (most commonly the RADyK group and the Transferrin) and/or the BBB itself was irradiated with paired-pulsed laser or MRgFUS. The GNPs were used for therapeutic purposes by the addition...
**TABLE 5** | Reference guide for the imaging modalities used in conjunction with gold nanoparticles (GNPs).

| Imaging modality                        | Brief description                                                                                                                                                                                                 |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MRI                                     | – An oscillating magnetic field characterized by a specific resonance frequency is applied to the patient.  
– The hydrogen atoms generate a radiofrequency signal, which is detected by the receiving coil.  
– The radio signal encodes the position information by changing the main magnetic field with gradient coils.  
– The rate at which the excited atoms return to the equilibrium state determines the contrast between different tissues (5).  
– Exogenous contrast agents (i.e., gadolinium) increase the contrast between different tissues. |
| Synchrotron-based CT                    | – A synchrotron source provides a high-flux, high-intensity, and monochromatic X-ray beam.  
– Synchrotron-based CT allows acquisition of quantitative high-resolution 3D CT images with a high signal-to-noise ratio (34). |
| Photoacoustic flow cytometry            | – Flow cytometry is based on a laser source focused on cells running into a high-speed, laminar, artificial flow.  
– The resulting scattered light is detected by a photodetector array (35).  
– The main limitation of flow cytometry is the extraction of cells *ex vivo*, with potential deterioration of the physical and molecular properties of the specimen.  
– Photoacoustic flow cytometry overcomes that limitation by allowing flow cytometry *in vivo*. Conceptually, the blood and lymphatic vessels serve as tubes where cells run in a laminar flow. The photoacoustic detector captures the acoustic waves generated by laser irradiation of the cells themselves. Then, GNPs are used as intracellular contrast agents (32). |
| Fluorescent microscopy                  | – The microscope detects the light emitted by a specimen when that is irradiated with light of a specific wavelength.  
– Fluorescent microscopy visualizes GNPs carrying a fluorescent tag on their surface (25). |
| Surface-enhanced Raman scattering (SERS) microscopy | – When light impinges on a substance, a modest percentage of its energy makes the molecules of the substance shift from the baseline to the excited state, leading to the absorption of the incident photon, and emission of a scattered photon (**Raman scattered photon**) (36).  
– The energy exchange, and the frequency shift, between the impinging photon and the scattered photon are known as the Raman effect.  
– **Raman imaging** is defined as an optical imaging modality based on the inelastic photon scattering upon interaction with matter (37).  
– Since different molecules emit different Raman signal (**Raman spectrum**), the Raman imaging is a valuable bioanalytical tool able to non-invasively differentiate molecules on the basis of their “optical fingerprint.”  
– In order to amplify the Raman scattering, which would be very weak in nature (38), Raman-active molecules are conjugated with metal nanoparticles. The resulting optical phenomenon is known as the SERS (38). |
| Tridimensional X-ray microscopy         | – X-ray microscopy is a contrast imaging technology based on the difference in absorption of soft X-rays in the water window region by the carbon atoms (main element composing the living cell) and by the oxygen atoms (main element for water) (39).  
– After passing through the specimen, X-rays are detected by a charge-coupled device detector that forms the image. |
| Optical microscopy                      | – The optical microscope (light microscope), uses visible light and a system of lenses to magnify images of small samples. |
| Photothermal cytometry (PTC)            | – The PTC is based on the temperature-dependent variation of the refractive index of a specimen irradiated with a laser.  
– The refractive index is detected by specific thermal lenses that allow formation of the image (32). |
| Fourier-transform infrared imaging (FTIR) | – FTIR is non-invasive optical fingerprinting of a biological specimen based on the analysis of light absorption different wavelength (33).  
– A computer infers what is the light absorption at each different wavelength, and forms an infrared spectrum of absorption of a solid, liquid, or gas. |
| Transmission electron microscopy (TEM)   | – TEM is based on irradiation of a thin specimen with electron beams of uniform current density.  
– The image is generated by the transmitted electrons through the specimen itself. |
| Photoacoustic microscopy (PAM)          | – PAM is an *in vivo* imaging technique that allows optical contrast detection, via the photoacoustic effect.  
– When photon beams are focused on a specimen, some of them are absorbed and their energy is converted into heat.  
– The heat induces a temporary pressure rise in the specimen propagating as a wideband acoustic wave.  
– The image is generated by an acoustic ultrasonic transducer that detects and localizes the acoustic waves in the specimen (40). |
| Multiphoton microscopy (MPM)            | – MPM, also known as two-photon microscopy (TPM), is based on the fluorescence emission by a specimen irradiated with photon beams.  
– MPM is ideal for studying biological specimens because it achieves a high-imaging depth (41). |
| Scanning electron microscopy (SEM)      | – SEM is based on detection of back-scattered and secondary electrons, when a specimen is irradiated with a high-energy beam of electrons in a raster scan pattern |
of a chemotherapeutic agent (doxorubicin) or a photosensitizer (Pg4) (Figure 2).

DISCUSSION

The Structural Elements of GNPs:
A Difficult Balance Between Tumor Penetration and Systemic Toxicity

The size of GNPs is critical for their physical, pharmacological, and toxic properties. The BBB is a complex barrier between the brain and the blood, which is formed by brain capillary endothelial cell tight junctions, luminal glyocalyx, basal lamina, and astrocytic foot processes. The intact BBB allows penetration of small lipophilic compounds, electroneutral compounds, and molecules under 600 Daltons. In order to use GNPs for brain imaging and/or for therapy, their size has to be tailored on the basis of the BBB restraints. Among the presented studies, the size of GNPs ranged between 20 and 120 nm, although the majority (12) had a size equal or less than 60 nm. Studies revealed that GNPs with a diameter up to 50 nm were able to pass BBB, as demonstrated by gold accumulation in the brain (42). About 0.3% of the intravenously injected GNPs with a 10 nm diameter can pass through the BBB into the brain, and this percentage remarkably drops as GNPs diameter increases (17, 42). In some studies, large GNPs (up to 120 nm) were able to cross the BBB after a temporary increase of BBB permeability, as achieved by MRgFUS (28). The size of GNPs is also critical for their toxicity. In fact, ultra-small GNPs (1.5 nm in diameter) were found to be highly cytotoxic, while approximately 10-fold larger GNPs (15 nm and above) were non-toxic at the same concentration levels (43). Thus, although there is an inverse proportion between GNP size and BBB penetration, there is not a similar correlation between size and toxicity. GNP shape can further complicate the scenario. A higher aspect ratio reduces GNPs toxicity and promotes cellular uptake (44). As an example, GNSs uptake is more efficient than GNRs uptake (44), and is less toxic (45). None of the papers on experiments performed on rodent models reported toxic reactions. Remarkably, 12 of the 13 studies performed, at least in part, using living rodent models, adopted GNSs. Other factors that might influence GNP toxicity include chemical preparation (46), high concentration, prolonged exposure (47), and the systemic route of administration (47). Nonetheless, GNPs are very biocompatible and induce minimal to no toxicity in healthy tissue (44).

The bioavailability of gold is largely dependent on the administration route. In the included papers, GNPs were injected in rodents intravenously, except when the xenograft itself was loaded with GNPs before implantation. In humans, gold preparations injected intravenously are fully absorbed within 2 h (48), while only one-fifth of the oral doses are absorbed (49). The gold diffuses to organs through the bloodstream, although the reticuloendothelial system has a remarkable affinity for the metal. Together, the liver and the bone marrow uptake 50% of injected gold (50), while the bone and skin uptake about 20% each (51). As noted above, less than 1% of injected GNPs reach the brain.

Thus, it is of paramount importance to minimize reticuloendothelial clearance of the gold, in order to maximize bioavailability for brain imaging. Various natural and synthetic polymers, including dextran (52), PEG (53), and poly(vinylpyrrolidone) (54), were employed as biocompatible coatings to prevent coagulation, promote particle monodispersion, and enhance systemic circulation of NPs. Among those, PEG was used to extensively cover the gold core of GNPs, in 9 of 13 studies performed in vivo. PEG is an FDA-approved biodegradable amphiphilic diblock copolymer with several advantages. First, PEG reduces GNPs clearance by the reticuloendothelial system and improves the exposure of the organs to GNPs (18); second, by reducing the reticuloendothelial clearance, PEG promotes GNPs accumulation in the brain tumor (55); third, PEG reduces potential intravascular aggregation of GNPs (aka "stealth effect"); fourth, PEG increases the retention of GNPs once there is tumor uptake (56); and fifth, the PEG coating serves as a platform for conjugation of further molecules to increase or broaden GNPs functionalities (20, 25).

Overcoming the “Enhanced Permeability and Retention” (EPR) Effect

In 1986, Maeda et al. observed that Evans blue binding albumin selectively accumulates in tumor tissue, after endovenous injection (57). The phenomenon was named “EPR” effect. Given the aberrant and exaggerated angioarchitecture and vascular permeability of tumors, heavy (>40 kDa) molecules can diffuse into tumor interstitial space and be retained because of impaired venous and, for some organs, lymphatic drainage. The EPR phenomenon leads to remarkable accumulation of heavy
(>40 kDa) molecules, such as drugs, at concentrations several folds higher than plasma. The prerequisites for the phenomenon to occur include a large molecular weight of drugs above the renal threshold, and a sufficiently high plasma concentration for a substantial amount of time (i.e., at least 6 h in mice and rat). The EPR effect still represents the pathophysiological basis for functioning of intravenously injected GNPs (19, 21). Nonetheless, the BBB of the tumor still partially limits the penetration of foreign molecules into the brain. Therefore, maximizing brain tumor uptake of GNPs is critical both for imaging and therapeutic purposes. Schematically, we divided the method for BBB penetration enhancement into two categories. The first included all molecules attached to GNPs surface ("internal enhancers"), and the second included all methods to increase BBB permeability by using an external source of energy ("external enhancers").

**Internal Enhancers**

Internal enhancers aim to selectively increase brain tumor uptake of GNPs, making them detectable for preoperative, intraoperative, and post-operative imaging techniques. As an example, since different glioma cell lines are characterized by a variable overexpression of EGFR (58), GNPs were functionalized with a monoclonal antibody anti-EGFR (Panitumumab) promoting their internalization by tumor cells (28).

Gold nanospheres were conjugated with RGDyK, an active ligand of the integrin αvβ3, a molecular marker overexpressed in about 30% of GBMs (20). At a microscopic level, GNPs conjugated with RGDyK enhanced tumor edges, loco-regional infiltration, and satellite foci remarkably better than non-integrin specific GNPs (20). Similarly, Gd-carrying GNPs were conjugated with a transactivator of transcription (TAT) peptide derived from HIV (TAT-GNP-Gd conjugates), in order to increase GNPs penetration through the BBB. These conjugates allowed a remarkably more intense and lasting tumor enhancement with respect to Gd alone (with a signal still detectable after 24 h) closely correlating with tumor invasion topography (41, 59). Importantly, TAT-GNP-Gd conjugates also cross the normal BBB, selectively accumulate within the most peripheral tumor cells, and are washed out from normal brain tissue (27).

Gold nanoparticles were also conjugated with multiple ligands in order to promote their uptake by cells with different molecular profiles within the same tumor mass ("molecular heterogeneity"). As an example, dual-receptor GNPs, functionalized both with FGF and transferrin, were able to cross the BBB more efficiently and accumulate more intensely in the tumor with respect to untargeted GNPs or transferrin-only targeted GNPs (25, 26).

Importantly, enhanced accumulation of functionalized GNPs into the brain did not lead to accumulation in other organs, as revealed by histological analysis of several different explanted organs (kidney, liver, heart, and lung) after injection of transferrin-functionalized GNPs (25) or after injection of dual-targeted (FGF and transferrin) GNPs (26). As a consequence, enhanced accumulation of functionalized GNPs into the tumor was not accompanied by systemic or brain toxicity.

The internal enhancers were also used for GNP targeting of tumors different than gliomas, such as breast cancer or melanoma metastases (32).

Internal enhancers were used to regulate GNPs aggregation inside the tumor itself. As an example, GNPs were functionalized with either the alkyne or azide chemical group. After passing through the BBB, the acidic environment typical of solid tumors promotes PEG degradation, exposure, and interaction of the functional alkyne and azide groups, allowing GNPs aggregation. Thus, GNPs rapidly form 3D spherical nanoclusters with characteristic Raman signal and MR enhancement persisting in the brain tumor interstitium for days. Conversely, GNPs diffusing in the normal brain, do not aggregate in the neutral pH environment, and are washed out (21).

**External Enhancers**

External enhancers include all the external sources of energy promoting BBB permeabilization, such as MRgFUS (28) and laser irradiation (29). MRgFUS was used to transiently enhance the BBB permeability in order to allow very large GNPs (ranging from 50 to 120 nm) to pass through the BBB.

Next, because of the unique physical properties of GNPs, a low-power (i.e., 35 mW) laser was used to radiate a brain tumor and elicit selective extravasation of the GNPs through the BBB of the tumor, but not of healthy brain. Interestingly, this phenomenon is limited to GNPs use. Indeed, tumor irradiation with a laser of similar power did not induce extravasation of traditional contrast agents. Thus, the mechanism of tumor BBB permeation might be attributed either to direct photothermal effect or to inflammation induced by energy burst (29). The main advantage of external enhancers is that these allow oversized GNPs to cross the BBB. The conceptual limitation of this approach is that GNPs cross the BBB only in pre-treated areas. Thus, tumor invasion boundaries should be known a priori. Conversely, the aim of using diagnostic GNPs is in contrast to this, namely to achieve an ultra-sensitive detection of tumor edges at a macroscopic and microscopic level. Ideally, GNPs should be engineered to diffuse freely in the brain parenchyma and to be retained only in brain tumor cells, providing an accurate “mapping” of brain tumor invasion.

**Imaging Methods: From Macrostructures to Nanostructures**

Gold nanoparticles enabled imaging the development of tumors and the interaction between tumor and healthy brain tissue at different resolutions, ranging from a macroscopic level to a microscopic and to a subcellular level.

**Macroscopic Level**

The synchrotron-based head CT (SynCT) of GNPs-loaded glioma xenografts in rats, provided a 3D reconstruction of the tumor volume and shape (31, 34). This resulted in a higher spatial resolution than PET (6–8 mm) and even MRI (1 mm) (60) which is considered the "gold standard" for brain tumor diagnosis and follow-up (30). Additionally, by measuring the dilution of GNPs within subsequent tumor cells generations, SynCT allows measuring and mapping replication rates of different tumor sections.
(31). Unfortunately, the present approach has a limited potential for use in humans for two main reasons. First, CT imaging requires a radiation dose that might not be acceptable to humans; and second, GNP-Gd conjugates are loaded into glioma cells instead of being injected into the living animal, which does not exactly replicate the real-life scenario in humans.

On the other hand, Gd-enhanced MRI is used in daily practice. Unfortunately, Gd mainly enhances tumor portions characterized by increased BBB permeability (19, 21, 61). Thus, the main limitation of MRI is that it does not enhance the most peripheral portion of the tumor, where highly active tumor cells infiltrate healthy brain parenchyma without an extensive BBB disruption and neoangiogenesis (8). A complete tumor resection is theoretically not possible because of imprecise tumor visualization. When compared with Gd alone, GNP-Gd conjugates allowed a remarkably more intense (up to 82-fold higher intracellular Gd concentration) and more lasting enhancement of the brain tumor, with signal still detectable after 24 h. Enhancement closely correlates with the whole tumor mass (19, 21, 27). Importantly, GNP-Gd conjugates widely penetrate the normal brain parenchyma, and are quickly washed out. So, GNP-Gd conjugates are able to cross the BBB regardless of its integrity, selectively accumulate within the tumor cells or, otherwise are removed from normal brain tissue, as expected according to the EPR effect (57). From a practical standpoint, GNP-Gd conjugates improve tumor visualization and, in the future, might improve extent of resection. Additionally, prolonged tumor enhancement might allow for improved intraoperative MRI imaging. Intraoperative MRI is mainly limited because iatrogenic BBB disruption during surgery affects Gd distribution and, as a consequence, visualization of tumor borders (62). Conversely, if GNP-Gd conjugates are injected preoperatively, tumor resection may occur in a stepwise manner by intraoperative MRI with no need of further contrast injections, allowing for both improved diagnostic accuracy and no additional Gd-induced toxicity. Additionally, the need for quantitative and qualitative estimation of brain shift during surgery would be not practically relevant anymore, since identification of tumor edges would not depend on finding a correspondence between intraoperative and preoperative landmarks.

Microscopic Level

Several techniques were applied to microscopic detection of tumor spread in the brain (Table 4). From a practical viewpoint, a few of them are suitable for the clinical practice.

The photoacoustic flow cytometry (PAFC) has been used to detect breast cancer metastases in vitro and in vivo (32).

Breast cancer orthotopic xenograft bearing mice were injected with GNP-Gd conjugates into the tumor. In the following days, a photoacoustic probe approximated to the mice cisterna magna, revealed the metastatic spread of breast cancer cells containing GNP-Gd conjugates. PAFC detected the metastatic cells in the CSF well before macroscopic brain metastases became radiologically evident. The implementation of this technique in humans might drastically change the diagnosis of brain metastases and, potentially, the timing of treatment.

Recently, the use of fluorescent markers was found to be useful for detection of microscopic tumor foci during surgery. 5-aminolevulinic acid (5-ALA), a fluorescent tumor maker, marks tumor edges intraoperatively with good sensitivity, and spatial resolution. This has been associated with increased progression-free survival in patients affected with gliomas (63). The use of 5-ALA as tumor marker has some technical limitations. First, the natural emission of light by biological structures (autofluorescence) can result in false positives and limited depth penetration of the signal; second, fast photochemical destruction (known as “photobleaching”) limits the time of tumor enhancement (37); and third, the large spectral overlap with other fluorescent imaging agents prevents the detection of multiple targets simultaneously (known as “multiplexing”) (47). Several fluorescent tumor markers have been conjugated with GNP-Gd conjugates in order to increase selectivity of intracellular uptake by tumor cells. As an example, fluorescent markers, such as cytochrome 647 (26) and Pc4 (28), conjugated with GNP-Gd allowed fluorescent microscopy localizing and quantifying intracellular uptake of GNP-Gd conjugates by tumor cells as well as by normal brain tissue and peripheral organs. Thus, the fluorescent GNP-Gd conjugates might be used for accurate intraoperative detection of residual tumor foci. Fluorescent GNP-Gd conjugates can be further functionalized with Raman tags (28). Although Raman imaging is not currently available in the neurosurgical practice, in experimental models, SERS microscopy revealed that GNP-Gd conjugates provide stable enhancement of tumor edges, the loco-regional infiltration (corresponding to the GBM digitations) and even the satellite foci remote from the main tumor mass, strongly correlating with spatial distribution of GBM histological markers (20, 21, 28).

Importantly, Raman signal is more stable and intense with respect to fluorescent markers such as 5-ALA (64). GNP-Gd conjugated with Raman tags might be the basis for intraoperative detection of GBM cells with SERS. Additionally, the photostability of Raman-active GNP-Gd conjugates might allow a more persistent signal emission with respect to fluorescent markers.

Nanoparticle multiplexing allows for performing multiple image modalities using the same NP. As an example, GNP-Gd conjugates served as contrast agents for macroscopic imaging (MRI and PAFC) as well as for microscopic imaging (SERS microscopy) (19). The triple-modality NP, known as MPR (magnetic resonance–photoacoustic–Raman) NP caused stable enhancement of tumor edges and loco-regional infiltration even after 24 h post-endovenous injection, with robust correlation in the spatial distribution of the signal between the three modalities.

Subcellular Level

Several different techniques were employed to study the intracellular distribution of GNP-Gd conjugates and the tumor pathophysiology. As an example, transmission electron microscopy visualizes the interaction and penetration of GNP-Gd conjugates through the tumor membrane, the interactions of GNP-Gd conjugates inside the tumor cells, and the ejection of GNP-Gd conjugates from the cellular membrane (22). A correlative optical and scanning electron microscopy (SEM) technique visualized the GNP-Gd conjugates accumulation in the brain tumor cells in experimental rodent models (24). SEM alone is not able to distinguish tumor from healthy tissue, while it allows an accurate definition of the size, shape, and structure of NPs. Thus, the GNP-Gd conjugates can be visualized as well as be localized inside
1. Diagnosis/ Follow-up Imaging (MRI)

2. Intraoperative Imaging (ioMRI)

3. Image-guided Microscopic Resection (SERS, Fluorescence, PAFC)

4. Post-operative Treatment (Chemotherapy/Radiation)

The brain tumor diagnosis is achieved by advanced brain magnetic resonance imaging (MRI) with gadolinium-conjugated gold nanoparticles (GNPs). After the usual surgical debulking of the tumor mass, the loco-regional invasion is identified and removed in two steps: a macroscopic phase [using intraoperative MRI (ioMRI)] and a microscopic phase involving GNPs suitable for Raman imaging, fluorescent imaging, photoacoustic imaging, and photoacoustic flow cytometry. The GNPs can be loaded with therapeutic agents, such as chemotherapy agents, that can target and destroy potential tumor residuals. If the tumor should recur, the cycle may be repeated.

FIGURE 3 | The theranostic cycle. (1) The brain tumor diagnosis is achieved by advanced brain magnetic resonance imaging (MRI) with gadolinium-conjugated gold nanoparticles (GNPs). (2) After the usual surgical debulking of the tumor mass, the loco-regional invasion is identified and removed in two steps: a macroscopic phase [using intraoperative MRI (ioMRI)] and a microscopic phase involving GNPs suitable for Raman imaging, fluorescent imaging, photoacoustic imaging, and photoacoustic flow cytometry. (3) The GNPs can be loaded with therapeutic agents, such as chemotherapy agents, that can target and destroy potential tumor residuals. If the tumor should recur, the cycle may be repeated.

the cells (with a spatial accuracy of 10 µm), by overlaying the SEM and optical images.

Lai et al. (23) reported using X-ray microscopy to visualize the aberrant microvasculature associated with the development of brain tumors. X-ray microscopy provided the first evidence of GNPs leaking through the BBB defects of brain tumors, in contrast to the normal brain tissue unaffected by GNPs leaking. Then, Fourier-transform infrared imaging was used to characterize different patterns of tumor angiogenesis on the basis of the specific size of fenestrations, by injecting at the same time GNPs of different sizes (33).

“Theranostic” GNPs: The Therapeutic Side of Diagnostic GNPs

Nanoparticles can behave simultaneously as diagnostic agents, therapeutic agents, and as markers of response to chemotherapy and radiation therapy (65, 66). NPs functioning both for diagnostic and therapeutic purposes are defined as “theranostic” NPs. As an example, GNPs were conjugated with photosensitizers such as Pc4. These GNPs can be used for diagnostic purposes because of their fluorescence, as well as, for therapeutic purposes. When irradiated with a laser, Pc4 causes photosensitization, and cell death (26).

Additionally, GNPs can be used as carriers for chemotherapy agents that cannot cross the BBB under physiological conditions. As an example, doxorubicin is highly effective on glioma cells in vitro, and is 2,000-fold more powerful than the standard-of-care temozolomide (67). Unfortunately, doxorubicin was abandoned as a chemotherapy agent for glioma in humans because it is not able to cross the BBB. Doxorubicin conjugated with GNPs (GNP-Dox) has different pharmacokinetic properties than doxorubicin injected alone. First, after intravenous injection, almost the entire amount of GNP-Dox passed through the BBB and entered the glioma cells; second, GNP-Dox caused no toxic effect on healthy brain or on other organs such as spleen, liver, kidney, and heart; third, since the link between GNPs and Doxorubicin was achieved by an acid-labile hydrazone group, the GNP-Dox could selectively release doxorubicin within the acidic environment of the lysosomes (pH = 4.5–6.0), leading to glioma cell death. As a consequence, a highly selective and highly concentrated topical chemotherapy is achieved, with no adverse effects. The use of GNPs as chemotherapy carriers might open the door to reconsider other agents that are currently not deemed efficacious for brain tumor treatment.

LIMITATIONS

At the moment, the interaction of the structural features of GNPs with their physical, biological, and toxic properties is not completely clear. A more detailed understanding would be crucial to maximize brain tumor uptake and to minimize the potential toxic effects on humans. Additionally, a quantitative and statistical comparison between the results of the included studies was not possible, because of the heterogeneity of the biological
models, as well as, of the structural and biological features of the used GNPs.

Importantly, our review did not provide any evidence of ongoing or completed clinical trials. Thus, all the conclusions regarding the potential applications of GNPs for brain tumor diagnosis and treatment should be considered field of ongoing research. A clinical application is still not available. Nonetheless, ample experience in the use of gold for medical purposes (i.e., rheumatoid arthritis) makes GNPs promising agents for brain tumor diagnosis and treatment in humans.

CONCLUSION

Gold nanoparticles are highly selective contrast agents for preoperative, intraoperative (with macroscopic and microscopic resolution), and post-operative imaging of primary and metastatic brain tumors. In comparison with Gd alone, GNPs can persist in the tumor mass for hours and potentially days after a single injection. The selectivity of GNPs for brain tumor cells, their prolonged retention in the tumor itself, as well as their effectiveness as therapeutic agents provides the theoretical basis for the “theranostic cycle” of GNPs (Figure 3). Injected GNPs allow for accurate delineation of the tumor mass and its loco-regional invasion, as visualized by MRI. Once tumor debulking has been completed, intraoperative imaging might allow for detailed macroscopic (by intraoperative MRI) and microscopic (by Raman imaging and fluorescent imaging) detection and removal of loco-regional tumor invasion. Next, the most remote satellite brain tumor foci can be treated with local focused chemotherapy. Should the tumor recur, a new “theranostic cycle” can be repeated because of the minimal toxicity of GNPs in vivo.

NOMENCLATURE

| Abbreviation | Full Form |
|--------------|-----------|
| GNP | Gold nanoparticle |
| GNP-Dox | GNP conjugated with doxorubicin |
| GNR | Gold nanorod |
| GNS | Gold nanosphere |
| GNSt | Gold nanostar |
| LRP-1 | Low-density lipoprotein-receptor-related protein-1 |
| MPM | Multiphoton microscopy |
| MPR | Magnetic resonance imaging–photoacoustic imaging–Raman imaging |
| MRgFUS | MRI-guided focused ultrasound |
| MRI | Magnetic resonance imaging |
| MUA | Mercapto-urodecanoic acid |
| NP | Nanoparticle |
| PAFc | Photoacoustic imaging |
| PAM | Photoacoustic microscopy |
| PEG | Polyethylene glycol |
| PFS | Progression-free survival |
| Pt4 | Phthalocyanine 4 |
| PTC | Photothermal cytometry |
| PVP | Poly(vinylpyrrolidone) |
| RADyK-GNS | Gold nanostar conjugated with protein RADyK |
| RADyK-GNC | Gold nanocage conjugated with protein RADyK |
| RGDyK-GNS | Gold nanostar conjugated with integrin RGDyK |
| RGDyK-GNC | Gold nanocage conjugated with integrin RGDyK |
| SEM | Scanning electron microscopy |
| SERS | Surface-enhanced Raman scattering |
| SynCT | Synchrotron-based CT |
| TAM | Transactivator of transcription |
| TEM | Transmission electron microscopy |
| TFI | Transferin |
| TXM | Tridimensional X-ray microscopy |
| 5-ALA | 5-aminolevulinic acid |

AUTHOR CONTRIBUTIONS

AM and SC concept and design, AM and NC data collection and tables and figures, AM, JR, SC, and MS analysis of data, AM and JR drafting of the paper, JR and SC critical review of the manuscript, All the authors final approval.

ACKNOWLEDGMENTS

We are grateful for support from Carol Bade and Craig and Kim Darian to SC.

FUNDING

Carol Bade and Craig and Kim Darian supported SC.

REFERENCES

1. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol (2003) 30(6 Suppl 19):10–4. doi:10.1053/j.seminoncol.2003.11.031
2. Duffau H. Surgery of low-grade gliomas towards a ‘functional neurooncology’. Curr Opin Oncol (2009) 21(6):543–9. doi:10.1097/CCO.0b013e3283305996
3. Duffau H. Brain Mapping: From Neural Basis of Cognition to Surgical Applications. Wien/New York: Springer (2011). xii, 392 p.
4. Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg (2014) 121(5):1115–23. doi:10.3171/2014.7.JNS132449
5. McRobbie DW. MRI from Picture to Proton. 2nd ed. Cambridge, UK/New York: Cambridge University Press (2007). xii, 394 p.
6. Brindle KM, Izquierdo-Garcia JL, Lewis DY, Mair RJ, Wright AJ. Brain tumor imaging. J Clin Oncol (2017) 35(21):2432–8. doi:10.1200/JCO.2017.72.7636
7. Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol (2006) 27(3):475–87.
8. Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg (2016) 124(4):977–88. doi:10.3171/2015.5.JNS142087
9. Ewelt C, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, et al. Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI.
FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurosurg (2011) 113(7):541–7. doi:10.1016/j.cjneuro.2011.03.008

10. Youngs M, Hoheisel JD, Effert T. Therapeutic and diagnostic applications of nanoparticles. Curr Drug Targets (2011) 12(3):357–65. doi:10.2174/138945011794815257

11. Nune SK, Gunda P, Thallapally PK, Lin YY, Forrest ML, Berkland CJ. Nanoparticles for biomedical imaging. Expert Opin Drug Deliv (2009) 6(11):1175–94. doi:10.1517/1742524903229031

12. Shubayev VI, Pisanic TR II, Jin S. Magnetic nanoparticles for theragnostic. Adv Drug Deliv Rev (2009) 61(6):467–77. doi:10.1016/j.addr.2009.03.007

13. Thakor AS, Jokerst JV, Zavaleta C, Massoud TF, Gambhir SS. Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett (2011) 11(10):4029–36. doi:10.1021/nl202255p

14. Saha K, Agasti SS, Kim C, Li X, Rotello VM. Quantitative analysis of gold nanoparticles: a revival in precious metal administration to patients. Nano Lett (2010) 6(8):1075–84. doi:10.1021/nl1013859

15. Marcelli A, Noreen R, Zhou J, Wilfinger J, Chien CC, Cestelli-Guidi M, Hwu Y. Gold nanoparticles in chemical and biological sensing. Chem Rev (2012) 112(5):2739–79. doi:10.1021/cr2001178

16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 339:b2700. doi:10.1136/bmj.b2700

17. Cho EC, Zhang Y, Cai X, Moran CM, Wang LV, Xia Y. Quantitative analysis of the fate of gold nanocages in vitro and in vivo after uptake by U87-MG tumor cells. Angew Chem Int Ed Engl (2013) 52(4):1152–5. doi:10.1002/anie.201208096

18. De Jong WH, Hagens WJ, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials (2008) 29(12):1912–9. doi:10.1016/j.biomaterials.2007.12.037

19. van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modified anatase TiO2 nanoparticles for tumor-targeted and intracerebral delivery. Pharm Res (2007) 24(8):1405–14. doi:10.1007/s11095-007-9284-6

20. Kircher MF, de la Zerda A, Jokerst JV, Zavaleta CL, Kempen PJ, Mittra E, et al. A brain tumor molecular imaging strategy using a new triple-modality MRI/photoacoustic–Raman nanoparticle. Nat Med (2012) 18(5):829–34. doi:10.1038/nm.2721

21. Huang R, Harmsen S, Samii JM, Karabeber H, Pitter KL, Holland EC, et al. High precision imaging of microscopic spread of glioblastoma with a surface-enhanced resonance Raman scattering nanostar for high-precision cancer imaging. Sci Transl Med (2015) 7(271):271ra7. doi:10.1126/scitranslmed.3001633

22. Etchegoin PG, Meyer M, Blackie E, Le Ru EC. Statistics of single-molecule enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance. J Am Chem Soc (2012) 134(28):11358–61. doi:10.1021/ja304180y

23. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, et al. Size-dependent cytotoxicity of gold nanoparticles. Small (2007) 3(11):1941–9. doi:10.1002/smll.200700378

24. Noreen R, Pineau R, Chien CC, Cestelli-Guidi M, Hwu Y, Marcelli A, et al. A correlative optical microscopy and scanning electron microscopy analysis of Au nanoparticles as multimodality imaging agents for brain gliomas. J Nanobiotechnology (2015) 13:85. doi:10.1186/s12951-015-0140-2

25. Dixit S, Novak T, Miller K, Zhu Y, Kenney ME, Broome AM. Transferrin enhanced and optically modulated delivery of gold nanostars into brain tumors. Nanoscale (2014) 6(8):4078–82. doi:10.1039/c3nr06777s

26. Galanzha EI, Zharov VP. Photoacoustic flow cytometry. Methods (2012) 57(3):280–96. doi:10.1016/j.ymeth.2012.06.009

27. Yuan H, Wilson CM, Xia J, Doyle SL, Li S, Fales AM, et al. Enhanced and optically modulated delivery of gold nanostars into brain tumor. Nanoscale (2014) 6(8):4078–82. doi:10.1039/c3nr06777s

28. Harmsen S, Huang R, Wall MA, Karabeber H, Samii JM, Spalvieri E, et al. Functional histology of glioma vasculature by FTIR imaging. Anal Bioanal Chem (2011) 401(3):795–801. doi:10.1002/anie.201005775

29. Salome M, Peyrin F, Cloetens P, Odet C, Laval-Jeantet AM, Baruchel J, et al. A synchrotron radiation microtomography system for the analysis of trabecular bone samples. Med Phys (1999) 26(10):2194–204. doi:10.1118/1.598736

30. Schultke E, Menk R, Pinzer B, Astolfo A, Stampanoni M, Arfelli F, et al. Dual-targeted therapeutic and imaging nanoparticles with acid-triggered MRI/FET-PET, and intraoperative, ALA-derived tissue fluorescence. Adv Drug Deliver Rev (2007) 61(6):467–77. doi:10.1016/j.addr.2009.03.007

31. Cho EC, Zhang Y, Cai X, Moran CM, Wang LV, Xia Y. Quantitative analysis of the fate of gold nanocages in vitro and in vivo after uptake by U87-MG tumor cells. Angew Chem Int Ed Engl (2013) 52(4):1152–5. doi:10.1002/anie.201208096

32. De Jong WH, Hagens WJ, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials (2008) 29(12):1912–9. doi:10.1016/j.biomaterials.2007.12.037
52. Berry CC, Wells S, Charles S, Aitchison G, Curtis AS. Cell response to dextran-derivatised iron oxide nanoparticles post internalisation. *Biomaterials* (2004) 25(23):5405–13. doi:10.1016/j.biomaterials.2003.12.046
53. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomaterials* (2005) 26(18):3995–4021. doi:10.1016/j.biomaterials.2004.10.012
54. D’Souza AI, Schowen RL, Topp EM. Polyvinylpyrrolidone-drug conjugate: synthesis and release mechanism. *J Control Release* (2004) 94(1):91–100. doi:10.1016/j.jconrel.2003.09.014
55. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. *Science* (1994) 263(5153):1600–3. doi:10.1126/science.8128245
56. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. *Crit Rev Ther Drug Carrier Syst* (2003) 20(5):357–403. doi:10.1615/CritRevTherDrugCarrierSyst.v20.i5.20
57. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. *J Drug Target* (2007) 15(7–8):457–64. doi:10.1080/10611860701539584
58. Voigt M, Braig F, Gothel M, Schulte A, Lamszus K, Bokemeyer C, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. *Neoplasia* (2012) 14(11):1023–31. doi:10.1593/neo.121242
59. Krpetic Z, Saleemi S, Prior IA, See V, Qureshi R, Brust M. Negotiation of intracellular membrane barriers by TAT-modified gold nanoparticles. *ACS Nano* (2011) 5(6):5195–201. doi:10.1021/nn10369k
60. Patel P, Papineni RV, Gupta S, Stoyanova R, Ahmed MM. A realistic utilization of nanotechnology in molecular imaging and targeted radiotherapy of solid tumors. *Radiat Res* (2012) 177(4):483–95. doi:10.1667/RR2597.1
61. Cheng Y, Meyers JD, Agnes RS, Doane TL, Kenney ME, Broome AM, et al. Addressing brain tumors with targeted gold nanoparticles: a new gold standard for hydrophobic drug delivery? *Small* (2011) 7(16):2301–6. doi:10.1002/smll.201100628
62. Olubiyi Ol, Ozdemir A, Inceker A, Tie Y, Dolati P, Hsu L, et al. Intraoperative magnetic resonance imaging in intracranial glioma resection: a Single-Center, Retrospective Blinded Volumetric Study. *World Neurosurg* (2015) 84(2):328–36. doi:10.1016/j.wneu.2015.04.044
63. Tonn JC, Stummer W. Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls. *Clin Neurosurg* (2008) 55:20–6.
64. Nie S, Emory SR. Probing single molecules and single nanoparticles by surface-enhanced Raman scattering. *Science* (1997) 275(5303):1102–6. doi:10.1126/science.275.5303.1102
65. Bian X, Song ZL, Qian Y, Gao W, Cheng ZQ, Chen L, et al. Fabrication of graphene-isolated-Au-nanocrystal nanostructures for multimodal cell imaging and photothermal-enhanced chemotherapy. *Sci Rep* (2014) 4:6603. doi:10.1038/srep06603
66. Ferrari M. Cancer nanotechnology: opportunities and challenges. *Nat Rev Cancer* (2005) 5(3):161–71. doi:10.1038/nrc1566
67. Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. *Anticancer Res* (2005) 25(6B):3825–31.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Meola, Rao, Chaudhary, Sharma and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.